Stay updated on Clinical Trial: Nivolumab in HCC with Electroporation
Sign up to get notified when there's something new on the Clinical Trial: Nivolumab in HCC with Electroporation page.

Latest updates to the Clinical Trial: Nivolumab in HCC with Electroporation page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe webpage has undergone significant updates, including the addition of a new clinical study on Hepatocellular Carcinoma (HCC) involving Nivolumab, with details on the study's phase, collaborators, and inclusion criteria. Notably, previous content regarding percutaneous ablation as a treatment for HCC has been removed.SummaryDifference42%
- Check34 days agoChange DetectedThe web page has been updated from version v2.14.3 to v2.14.4.SummaryDifference0.1%
- Check41 days agoChange DetectedThe web page has been updated to version 2.14.3, replacing the previous version 2.14.2.SummaryDifference0.1%
- Check77 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check91 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Clinical Trial: Nivolumab in HCC with Electroporation
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Nivolumab in HCC with Electroporation page.